Hans D. Menssen

Supplementary Data from MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production

Marlene Langenbach, Sophie Giesler, Stefan Richtsfeld, Sara Costa-Pereira et autres

Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia

Romain Séchaud, Thomas Peters, Helen Gu, Gholamreza Rahmanzadeh et autres

ch, us, in (code pays fourni par la source)

Isolated oral CD30+/CD4+ CAR+ T cell lymphoma in long-term remission after radiotherapy

Evandro D. Bezerra, Ludmila Lupu, M. Lima, Lena Pfaller et autres

us, ch, cn (code pays fourni par la source)

Aggressive Lymphoma after CD19 CAR T-Cell Therapy

Guido Kobbe, Monika Brüggemann, Ben‐Niklas Baermann, Laura Wiegand et autres

de, by (code pays fourni par la source)

Data from MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production

Marlene Langenbach, Sophie Giesler, Stefan Richtsfeld, Sara Costa-Pereira et autres

Supplementary Data from MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production

Marlene Langenbach, Sophie Giesler, Stefan Richtsfeld, Sara Costa-Pereira et autres

Supplementary Data from MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production

Marlene Langenbach, Sophie Giesler, Stefan Richtsfeld, Sara Costa-Pereira et autres

OA-12 Interim Phase 2 Study Results of Durcabtagene Autoleucel (PHE885), a T-Charge™ Manufactured BCMA-Directed CAR-T Cell Therapy in Patients (pts) with r/r Multiple Myeloma (RRMM)

Andrew Spencer, Marc S. Raab, Shinsuke Iida, María-Victoria Mateos Manteca et autres

Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants

Romain Séchaud, Helen Gu, Gholamreza Rahmanzadeh, Ovidiu Chiparus et autres

ch, us (code pays fourni par la source)

Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti–TIM-3 therapy in mice

Nana Talvard-Balland, Lukas M. Braun, Karen O. Dixon, Melissa Zwick et autres

de, jp, us, ch, it (code pays fourni par la source)

Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

Romain Séchaud, Helen Gu, Gholamreza Rahmanzadeh, Amanda Taylor et autres

ch, us, in (code pays fourni par la source)

Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

Romain Séchaud, Helen Gu, Gholamreza Rahmanzadeh, Amanda Taylor et autres

ch, us, in (code pays fourni par la source)